| Phase 3 | Complicated Intra-abdominal Infection | - |
| Phase 3 | Hemophilia A | - |
13-valent pneumococcal conjugate vaccine | Phase 3 | Pneumococcal Vaccines | - |
| Phase 3 | Renal Cell Carcinoma | - |
| Phase 3 | HER2-positive Breast Cancer | - |
levonorgestrel/ethinyl estradiol | Phase 3 | Menstruation Disturbances | - |
Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) | Phase 3 | Encephalitis, Tick-borne | - |
Bococizumab (PF-04950615;RN316) | Phase 3 | Hyperlipidemia | - |
| Phase 3 | Severe Alopecia Areata | - |
| Phase 3 | Community Acquired Pneumonia (CAP) | - |
| Phase 3 | COVID-19 | - |
| Phase 3 | Carcinoma, Pancreatic Ductal | - |
| Phase 3 | Sedation | - |
| Phase 3 | Major Depressive Disorder | - |
AN2690 Topical Solution, 5% | Phase 3 | Onychomycosis of Toenails | - |
AN2728 Topical Ointment, 2% | Phase 3 | Dermatitis, Atopic | - |
Dacomitinib (PF-00299804) | Phase 3 | Non-Small Cell Lung Cancer | - |
| Phase 3 | Overactive Bladder | - |
| Phase 3 | Vaccines, Pneumococcal | - |
| Phase 3 | BRAF V600E-mutant Metastatic Colorectal Cancer | - |
20-valent pneumococcal conjugate vaccine | Phase 3 | Pneumococcal Disease | - |
Talazoparib with enzalutamide | Phase 3 | mCRPC | - |
| Phase 3 | Tonsillitis | - |
Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT) | Phase 3 | Meningitis, Meningococcal | - |
| Phase 3 | Breast Neoplasms | - |
| Phase 3 | Breast Neoplasms | - |
| Phase 3 | Ejaculation | - |
| Phase 3 | Idiopathic Short Stature | - |
| Phase 3 | Asthma | - |
| Phase 3 | Pain | - |
oxycodone HCl and naltrexone HCl extended-release capsules | Phase 3 | Chronic Noncancer Pain | - |
| Phase 3 | Acute Migraine | - |
| Phase 3 | Migraine | - |
| Phase 3 | Overactive Bladder Syndrome | - |
| Phase 3 | Meningococcal Vaccine | - |
| Phase 3 | Non-Small Cell Lung Cancer | - |
Meningococcal vaccine GSK134612 | Phase 3 | Infections, Meningococcal | - |
13-valent pneumococcal conjugate vaccine (13vPnC) | Phase 3 | Healthy Subjects | - |
| Phase 3 | Gastroesophageal Reflux | - |
| Phase 3 | Hemophilia A | - |
| Phase 3 | Fibromyalgia | - |
Bazedoxifene/Conjugate Estrogens (CE) | Phase 3 | Endometrial Hyperplasia | - |
7-valent Pneumococcal Conjugate Vaccine | Phase 3 | Pneumococcal Infection | - |
| Phase 3 | Alzheimer Disease | - |
| Phase 3 | Osteoarthritis | - |
| Phase 3 | Overactive Bladder Syndrome | - |
Desvenlafaxine Succinate Sustained-Release 10mg | Phase 3 | Major Depressive Disorder | - |
olmesartan alone or in combination with hydrochlorothiazide | Phase 3 | Essential Hypertension | - |
| Phase 3 | Gaucher Disease | - |
| Phase 3 | Tinea Capitis | - |
| Phase 3 | Renal Cell Carcinoma | - |
Placebo to Week 16; tanezumab 5mg SC | Phase 3 | Low Back Pain | - |
7 valent pneumococcal conjugate vaccine | Phase 3 | Vaccines, Pneumococcal | - |
Inhaled human insulin (EXUBERA™) | Phase 3 | Diabetes Mellitus, Type 2 | - |
| Phase 3 | Overactive Bladder | - |
| Phase 3 | Diabetic Foot Ulcer | - |
| Phase 3 | Transthyretin (TTR) Amyloid Cardiomyopathy | - |
| Phase 3 | Endocrine System Diseases | - |
| Phase 3 | Carcinoma, Renal Cell | - |
| Phase 3 | Arthritis | - |
| Phase 3 | Vaccines, Pneumococcal Conjugate Vaccine | - |
| Phase 3 | Mycoses | - |
endocrine-modulating drug therapy | Phase 3 | Prostate Cancer | - |
Parecoxib Sodium/Valdecoxib | Phase 3 | Pain | - |
| Phase 3 | Pain | - |
Modified Bolus 5-FU/LV with Irinotecan | Phase 3 | Colorectal Neoplasms | - |
ceftazidim-avibactam (CAZ-AVI, experimental product) | Phase 3 | Nosocomial Pneumonia (NP) | - |
| Phase 3 | Rheumatoid Arthritis | - |
| Phase 3 | Non-small Cell Lung Cancer With EGFR-Activating Mutations | - |
| Phase 3 | Prostate Cancer | - |
| Phase 3 | Febrile Neutropenia | - |
Cyclosporin or tacrolimus | Phase 3 | Graft Rejection | - |
Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7) | Phase 3 | Neisseria Meningitidis (Bacterial Meningitis) | - |
| Phase 3 | Complicated Skin and Soft Tissue Infection | - |
Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg | Phase 3 | Oral Contraceptive | - |
Desvenlafaxine succinate sustained-release (DVS SR) | Phase 3 | Depression | - |
| Phase 3 | Ankylosing Spondylitis | - |
| Phase 3 | Otitis Media | - |
| Phase 3 | Panic Disorder | - |
| Phase 3 | COVID-19 | - |
| Phase 3 | Pain | - |
amoxicillin/clavulanate postassium (Augmentin ES-600) | Phase 3 | Acute Otitis Media | - |
Epirubicin with Cyclophosphamide, followed by a Taxane | Phase 3 | Adenocarcinoma | - |
| Phase 3 | Smoking Cessation | - |
| Phase 3 | Menopause | - |
| Phase 3 | Meningococcal Vaccine | - |
| Phase 3 | Complicated Intra-abdominal Infection | - |
| Phase 3 | Attention Deficit Hyperactivity Disorder | - |
| Phase 3 | Acute Treatment of Migraine | - |
13 valent Pneumococcal Conjugate Vaccine | Phase 3 | Pneumococcal Infections | - |
Amoxicillin/clavulinic acid | Phase 3 | Bronchitis, Chronic | - |
7vPnc pneumococcal conjugate vaccine | Phase 3 | Vaccines, Pneumococcal | - |
| Phase 3 | Schizophrenia | - |
talazoparib plus enzalutamide | Phase 3 | Prostate Cancer | - |
| Phase 3 | Chronic Renal Failure Requiring Hemodialysis | - |
| Phase 3 | Gram-Positive Bacterial Infections | - |
| Phase 3 | Breast Neoplasms | - |
| Phase 3 | Pain | - |
| Phase 3 | Migraine | - |
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg | Phase 3 | Menopause | - |
Tick-borne Encephalitis Vaccine | Phase 2 | Tick-borne Encephalitis | - |
| Phase 2 | Alopecia Areata | - |
| Phase 2 | Diabetes Mellitus, Type II | - |
| Phase 2 | Psoriasis | - |
| Phase 2 | Diabetes | - |
| Phase 2 | Prostate Cancer | - |
| Phase 2 | Carcinoma, Non-Small-Cell Lung | - |
| Phase 2 | Diabetic Nephropathies | - |
ARRY-502, CRTh2 antagonist; oral | Phase 2 | Asthma | - |
| Phase 2 | Ovulation | - |
| Phase 2 | Respiratory Tract Infections | - |
| Phase 2 | Pneumococcal Infections | - |
| Phase 2 | Rheumatoid Arthritis | - |
| Phase 2 | Epilepsy, Partial | - |
| Phase 2 | Hepatitis | - |
| Phase 2 | Neutropenia | - |
| Phase 2 | Breast Cancer | - |
| Phase 2 | Psoriasis | - |
| Phase 2 | Neuroendocrine Tumors | - |
ARRY-438162, MEK inhibitor; oral | Phase 2 | Rheumatoid Arthritis | - |
| Phase 2 | Alzheimer's Disease | - |
FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil) | Phase 2 | Unresectable or Metastatic Colorectal Cancer | - |
| Phase 2 | Schizophrenia | - |
| Phase 2 | Chronic Myelogenous Leukemia | - |
| Phase 2 | Polycystic Kidney, Autosomal Dominant | - |
| Phase 2 | Hepatocellular Carcinoma | - |
| Phase 2 | Solid Tumors Harboring a BRAF V600 Mutation | - |
| Phase 2 | Gastrointestinal Stromal Tumors | - |
Tofacitinib ointment 20mg/g | Phase 2 | Dermatitis, Atopic | - |
| Phase 2 | Cervical Cancer | - |
| Phase 2 | Hypercholesterolemia | - |
| Phase 2 | Breast Cancer | - |
| Phase 2 | Crohn's Disease | - |
| Phase 2 | Colitis, Ulcerative | - |
| Phase 2 | Pulmonary Disease, Chronic Obstructive | - |
| Phase 2 | Pulmonary Arterial Hypertension | - |
| Phase 2 | Breast Neoplasms | - |
| Phase 2 | Urinary Incontinence, Stress | - |
| Phase 2 | Alzheimer Disease | - |
Elranatamab (PF-06863135) | Phase 2 | Multiple Myeloma | - |
| Phase 2 | Active Non-segmental Vitiligo | - |
Anti-Beta Interferon (PF-06823859) | Phase 2 | Dermatomyositis | - |
PF-07220060 + PF-07104091 combination dose escalation | Phase 2 | Breast Cancer | - |
| Phase 2 | Scar Prevention | - |
| Phase 2 | Alzheimer Disease | - |
| Phase 2 | Dyslipidemia | - |
| Phase 2 | Tibial Fractures | - |
| Phase 2 | Active Rheumatoid Arthritis | - |
PF-04494700 - Low Dose Arm | Phase 2 | Alzheimer Disease | - |
| Phase 2 | Metastatic Colorectal Cancer | - |
| Phase 2 | Fractures | - |
| Phase 2 | Arthritis, Rheumatoid | - |
| Phase 2 | Crohn's Disease | - |
BNT162b2 (Omi XBB.1.5)/RIV | Phase 2 | Influenza, Human | - |
| Phase 2 | Colitis, Ulcerative | - |
| Phase 2 | Non-small Cell Lung Cancer | - |
| Phase 2 | Hemophilia B | - |
| Phase 2 | Alcoholism | - |
| Phase 2 | Healthy | - |
ARRY-371797, p38 inhibitor; oral | Phase 2 | LMNA-Related Dilated Cardiomyopathy | - |
| Phase 2 | Prostatic Neoplasms | - |
| Phase 2 | Rheumatoid Arthritis | - |
| Phase 2 | Hepatitis, Chronic Active | - |
| Phase 2 | Chronic Low Back Pain | - |
| Phase 2 | Kidney Neoplasms | - |
| Phase 2 | Ulcerative Colitis | - |
| Phase 2 | Respiratory Tract Infection | - |
| Phase 2 | Non-small Cell Lung Cancer | - |
| Phase 2 | Urothelial Carcinoma | - |
| Phase 2 | Non-small Cell Lung Cancer | - |
| Phase 2 | Neutropenia | - |
| Phase 2 | HIV | - |
| Phase 2 | Hemophilia A | - |
| Phase 2 | SARS-CoV-2 Infection | - |
7-Valent Pneumococcal Conjugate Vaccine (7vPnC) | Phase 2 | Healthy Subjects | - |
| Phase 2 | Carcinoma, Non-Small-Cell Lung | - |
| Phase 2 | Heart Failure | - |
| Phase 2 | Carcinoma, Renal Cell Metastasis | - |
| Phase 2 | Kidney Transplantation | - |
| Phase 2 | Osteoarthritis | - |
| Phase 2 | Psoriasis | - |
| Phase 2 | Onychomycosis | - |
| Phase 2 | Meningococcal Vaccine | - |
| Phase 2 | Psoriasis | - |
| Phase 2 | Complicated Urinary Tract Infections | - |
| Phase 2 | Breast Neoplasms | - |
| Phase 2 | Non-Small-Cell Lung Carcinoma | - |
| Phase 2 | HIV-1 | - |
| Phase 2 | Postherpetic Neuralgia | - |
| Phase 2 | Pulmonary Fibrosis | - |
| Phase 2 | Endometriosis | - |
| Phase 2 | Generalized Anxiety Disorder | - |
| Phase 2 | Liposarcoma | - |
| Phase 2 | Acute Myeloid Leukemia (AML) | - |
| Phase 2 | Alzheimer's Disease | - |
| Phase 2 | Dry Eye Syndromes | - |
| Phase 2 | Asthma | - |
| Phase 2 | Diabetes Mellitus, Type 2 | - |
| Phase 2 | Complicated Intra-Abdominal Infections, cIAIs | - |
Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral | Phase 2 | Osteoarthritis of the Knee | - |
